Get the Stockscreener App
5.56
0.54%
-0.03
After Hours:
5.59
0.03
+0.54%
Savara Inc stock is traded at $5.56, with a volume of 1.32M.
It is down -0.54% in the last 24 hours and up +0.91% over the past month.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
See More
Previous Close:
$5.59
Open:
$5.6
24h Volume:
1.32M
Relative Volume:
0.75
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-129.48M
P/E Ratio:
-9.957
EPS:
-0.5584
Net Cash Flow:
$-106.97M
1W Performance:
+3.54%
1M Performance:
+0.91%
6M Performance:
-1.42%
1Y Performance:
+75.95%
1-Day Range:
$5.425
$5.60
1-Week Range:
$5.26
$5.64
52-Week Range:
$3.08
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.56 | 1.13B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Announces New Employment Inducement GrantAugust 20, 2026 - BioSpace
Savara (SVRA) Quarterly Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Response: Shares Move 3.91% Higher for the Current SessionEarnings Outlook Update - dars.gov.et
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11 - Moomoo
Savara (SVRA) Advances 2.09% to $5.38 as Aerosol Therapy Momentum BuildsStock Analysis - Vinanet
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Pipeline InvestmentPeak Earnings Alert - vinanet.vn
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11Triple Top - vinanet.vn
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA - MarketBeat
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Savara - MarketBeat
Savara (NASDAQ:SVRA) Stock Price Down 5.4%What's Next? - MarketBeat
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings - marketbeat.com
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
Savara Inc. (SVRA) Advances 1.17% as Rare Disease Focus Draws Continued Interest — Resistance at $5.91 in SightPrice Momentum Stocks - Vinanet
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Revenue Weighted - Vinanet
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
SAVARA Q2 EPS USD -0.16 - Moomoo
Savara Q2 loss widens to $40M on surging commercial costs - scanx.trade
Savara Inc (SVRA) Advances MOLBREEVI Launch Amid High Price-to-S - GuruFocus
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Savara Inc. Announces Q2 2026 Financial Results with Increased Net Losses - Kalkine Media
Savara Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Q2 loss widens as operating expenses rise - TradingView
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary - TradingView
BRIEF-Savara Q2 Net Income USD -40.228 Million - TradingView
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC - MarketBeat
Savara Inc (YB4P.SG) recent insider transactions - au.finance.yahoo.com
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 88.90% Potential Upside - DirectorsTalk Interviews
Savara investors brace for earnings ahead of crucial FDA review By Investing.com - Investing.com Nigeria
Savara (SVRA) to Announce Quarterly Earnings on Wednesday - MarketBeat
SVRA Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA) - Seeking Alpha
Savara's upcoming APAP BLA filing seen as key c... - Pluang
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
SVRA Q1 2026 Earnings: Wider Loss Than Expected as Pre-Revenue Biotech Navigates Pipeline CostsEarnings Weakness Phase - vinanet.vn
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA - MarketBeat
Savara Inc. (SVRA) Slips to $5.44 as Rare Disease Biotech Holds Support ZoneEase of Movement - dars.gov.et
Savara Inc. (SVRA) Gains 2% as Shares Test Key Resistance LevelsVolume Dry Up - dars.gov.et
Savara secures European, Australian patents for MOLBREEVI By Investing.com - Investing.com Nigeria
SVRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Savara Inc. $SVRA Shares Bought by Eversept Partners LP - marketbeat.com
SVRA|Savara Inc|Price:5.435|Chg%:-0.075 - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA - MarketBeat
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Jun 22 '26 |
Sale |
5.68 |
394,528 |
2,241,432 |
536,032 |
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):